NCT07608432Phase 3Recruiting

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Study sponsor: Dyne Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-12Estimated
Enrollment · participants90Estimated
Source updated2026-05-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.